Fig. 5From: Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systemsCharacterisation of the potential interaction between solid drug nanoparticles and lymphocyte function. PBMC were treated with either efavirenz aqueous solution or efavirenz s for 24 h before their proliferative capacity (a), cytokine secretion (b) and surface marker expression in CD4+ (c) and CD8+ (d) cells were determined. Data expressed as mean ± standard deviation (N = 5); *P < 0.05, **P < 0.01, ***P < 0.001 as compared to untreated control whereas $P < 0.05, $$P < 0.01, $$$P<0.001 compared to positive controlBack to article page